Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

Van Den Brande, Jan M. H.; Koehier, Tamara C.; Zelinkova, Zuzana; Bennink, Roelof J.; Te Velde, Anje A.; Ten Cate, Fibo J. W.; Van Deventer, Sander J. H.; Peppelenbosch, Maikel P.; Hommes, Daniël W.
April 2007
Gut;Apr2007, Vol. 56 Issue 4, p509
Academic Journal
Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TNF and subsequently induces apoptosis of activated lamina propria T lymphocytes in patients with Crohn's disease in vitro. Aim: To test whether the ability of rapid anti-TNF-induced apoptosis in the gut predicts the efficacy of anti-TNF treatment in inflammatory bowel disease. Methods: 99mTechnetium-annexin V single-photon emission computer tomography (SPECT) was performed in 2 models of murine experimental colitis and in 14 patients with active Crohn's disease as assessed by the Crohns Disease Activity Index (CDAI) to study the effect of anti-TNF treatment on apoptosis in the intestine during active colitis. Disease activity was evaluated 2 weeks after infliximab infusion using the CDAI (definition response: drop of >100 points). Results: Colonic uptake of 99mTc-annexin V significantly increased in 2,4,6-trinitrobenzene sulphonate- induced colitis as well as in transfer colitis on administration of anti-TNF antibodies compared with a control antibody as determined with dedicated animal pinhole SPECT. In addition, uptake of 99mTc-annexin V significantly increased in patients with active Crohn's disease responding to infliximab treatment. Colonic 99mTc-annexin V uptake ratio (mean (SEM)) increased from 0.24 (0.03) to 0.41(0.07) (p<0.01), 24 h after infliximab infusion (5 mg/kg). A mean increase of 98.7% in colonic uptake of 99mTc-annexin V could be detected in 10 of the 14 responding patients (CDAI >100 points at week 2) compared with 15.2% in non-responding patients (p=0.03). Analysis of the mucosal biopsy specimens identified lamina propria T cells as target cells undergoing apoptosis. Conclusions: These in vivo observations support the notion that colonic uptake of 99mTc-annexin V correlates with clinical benefit of anti-TNF treatment and might be predictive of therapeutic success.


Related Articles

  • Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies.  // BioDrugs;2010 Supplement 1, Vol. 24, p3 

    No abstract available.

  • Anti-Tumour Necrosis Factor Therapy for Ulcerative Colitis: Evidence to Date. Thukral, Chandrashekhar; Cheifetz, Adam; Peppercorn, Mark A. // Drugs;2006, Vol. 66 Issue 16, p2059 

    Infliximab, the chimeric monoclonal antibody directed against tumour necrosis factor (TNF)-α, has profoundly changed therapy for Crohn's disease (CD). However, for ulcerative colitis (UC), before the publication of ACT 1 and ACT 2 (Active Ulcerative Colitis Trials 1 and 2), there were only a...

  • Use of anti-tumour necrosis factor agents in inflammatory bowel disease: European guidelines for 2001–2003. Schreiber, S.; Campieri, M.; Colombel, J. F.; Van Deventer, S. J. H.; Feagan, B.; Fedorak, R.; Forbes, A.; Gassull, M.; Gendre, J. P.; Van Hogezand, R. A.; Lofberg, R.; Modigliani, R.; Pallone, F.; Petritsch, W.; Prantera, C.; Rampton, D.; Seibold, F.; Vatn, M.; Zeitz, M.; Rutgeerts, P. // International Journal of Colorectal Disease;Jan2001, Vol. 16 Issue 1, p1 

    The introduction of novel anti-tumor necrosis factor (TNF) agents has not only led to impressive new therapeutic opportunities but also resulted in uncertainty regarding their optimal use and possible side effects. Guidelines are presented here for the use of anti-TNF agents in gastrointestinal...

  • Mucosal T Cell Proliferation and Apoptosis in Inflammatory Bowel Disease. Sturm, Andreas; De Souza, Heitor S. P.; Fiocchi, Claudio // Current Drug Targets;May2008, Vol. 9 Issue 5, p381 

    Both forms of inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC), represent prototypical conditions whose most salient features are the presence of chronic inflammation involving various parts of the intestinal tract and an increased risk of cancer, which is a...

  • Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation. Caprioli, F; StoIfi, C; Caruso, R; Fina, D; Sica, G; Biancone, L; Pallone, F; Monteleone, G // Gut;Dec2008, Vol. 57 Issue 12, p1674 

    Objective: Defects in Fas-mediated apoptosis are supposed to contribute to the accumulation of T lymphocytes in the gut of patients with Crohn's disease (CD). This phenomenon has been functionally linked with the elevated expression of Flip, an inhibitor of Fas- mediated apoptosis. In this...

  • rApoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment. Veltkamp, Claudia; Anstaett, Matthias; Wahl, Kristin; Moöller, Sarah; Gangl, Saskia; Bachmann, Oliver; Hardtke-Wolenski, Matthias; Laönger, Florian; Stremmel, Wolfgang; Manns, Michael P; Schulze-Osthoff, Klaus; Bantel, Heike // Gut;Oct2011, Vol. 60 Issue 10, p1345 

    Background and aims Inappropriate immune responses contribute to the continuous stimulation of the intestinal immune system in chronic inflammatory bowel disease (IBD). Among several pathogenic factors, a numerical deficiency of regulatory T (Treg) cells has been suggested to lead to an...

  • Certolizumab Pegol: In Crohn's Disease.  // BioDrugs;2007, Vol. 21 Issue 3, p195 

    â–´ Certolizumab pegol is a pegylated humanized Fab' fragment of an anti-tumor necrosis factor-a (TNFa) monoclonal antibody, which binds with high affinity to both membrane-bound and soluble TNFa and demonstrates high neutralizing potency for these factors. â–´ The elimination half-life...

  • Leczenie podtrzymujÄ…ce remisjÄ™ w nieswoistych zapaleniach jelit. Neubauer, Katarzyna; Paradowski, Leszek // Gastroenterologia Polska / Gastroenterology;2010, Vol. 17 Issue 2, p129 

    Maintenance therapy in inflammatory bowel disease (IBD) involves 5′-aminosalicylate derivatives, immunosuppressive drugs (azathioprine, 6-mercaptopurine, methotrexate), and biological agents, which are a breakthrough in the therapy of IBD. Among the biological agents currently available in...

  • Safety profile of anti-tumor necrosis factor therapy in inflammatory bowel disease - a single center experience. Eder, Piotr; Łykowska-Szuber, Liliana; Krela-Kaźmierczak, Iwona; Stawczyk-Eder, Kamila; Klimczak, Katarzyna; Szymczak, Aleksandra; Linke, Krzysztof // Journal of Medical Science;2015, Vol. 84 Issue 3, p146 

    Introduction. The data on the safety profile of anti-tumor necrosis factor (anti-TNF) therapy in real-life patients cohorts with inflammatory bowel disease (IBD) still are lacking. Aim. The aim of the study was to assess the adverse events (AE) of anti-TNF therapy in a single Polish IBD center....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics